CRSP FY2024 EPS Lowered by Brookline Capital Management

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn ($5.18) per share for the year, down from their prior estimate of ($4.88). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.57) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $8.07 EPS, FY2027 earnings at $11.96 EPS and FY2028 earnings at $26.00 EPS.

Other equities research analysts also recently issued research reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research report on Wednesday. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Rodman & Renshaw assumed coverage on shares of CRISPR Therapeutics in a research report on Friday, August 2nd. They set a “buy” rating and a $90.00 target price on the stock. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of CRISPR Therapeutics in a research note on Thursday, August 8th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Trading Up 2.3 %

NASDAQ:CRSP opened at $51.88 on Friday. The firm has a market capitalization of $4.41 billion, a price-to-earnings ratio of -16.06 and a beta of 1.67. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10. The business’s fifty day moving average price is $47.38 and its 200 day moving average price is $52.24.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. The firm had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the previous year, the business earned ($1.41) earnings per share.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 4,293 shares of CRISPR Therapeutics stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now directly owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds have recently added to or reduced their stakes in CRSP. Global Trust Asset Management LLC raised its stake in shares of CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock valued at $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC raised its position in CRISPR Therapeutics by 99.7% in the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the last quarter. Itau Unibanco Holding S.A. acquired a new position in CRISPR Therapeutics during the 2nd quarter worth $35,000. Finally, Denver PWM LLC bought a new position in CRISPR Therapeutics in the 2nd quarter valued at $45,000. Institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.